These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11961122)

  • 1. Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor.
    Ding XQ; Pinon DI; Furse KE; Lybrand TP; Miller LJ
    Mol Pharmacol; 2002 May; 61(5):1041-52. PubMed ID: 11961122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of lysine187 within the second extracellular loop of the type A cholecystokinin receptor in agonist-induced activation. Use of complementary charge-reversal mutagenesis to define a functionally important interdomain interaction.
    Dong M; Ding XQ; Thomas SE; Gao F; Lam PC; Abagyan R; Miller LJ
    Biochemistry; 2007 Apr; 46(15):4522-31. PubMed ID: 17381074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
    Arlander SJ; Dong M; Ding XQ; Pinon DI; Miller LJ
    Mol Pharmacol; 2004 Sep; 66(3):545-52. PubMed ID: 15322246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
    Gigoux V; Maigret B; Escrieut C; Silvente-Poirot S; Bouisson M; Fehrentz JA; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy AD
    Protein Sci; 1999 Nov; 8(11):2347-54. PubMed ID: 10595537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.
    Harikumar KG; Pinon DI; Wessels WS; Dawson ES; Lybrand TP; Prendergast FG; Miller LJ
    Mol Pharmacol; 2004 Jan; 65(1):28-35. PubMed ID: 14722234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling.
    Ji Z; Hadac EM; Henne RM; Patel SA; Lybrand TP; Miller LJ
    J Biol Chem; 1997 Sep; 272(39):24393-401. PubMed ID: 9305898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
    J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.
    Dong M; Lam PC; Pinon DI; Abagyan R; Miller LJ
    Biochemistry; 2009 Jun; 48(23):5303-12. PubMed ID: 19441839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arginine 336 and asparagine 333 of the human cholecystokinin-A receptor binding site interact with the penultimate aspartic acid and the C-terminal amide of cholecystokinin.
    Gigoux V; Escrieut C; Fehrentz JA; Poirot S; Maigret B; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy D
    J Biol Chem; 1999 Jul; 274(29):20457-64. PubMed ID: 10400673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe.
    Ding XQ; Dolu V; Hadac EM; Holicky EL; Pinon DI; Lybrand TP; Miller LJ
    J Biol Chem; 2001 Feb; 276(6):4236-44. PubMed ID: 11050076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into the molecular basis of ligand binding by the cholecystokinin receptor.
    Miller LJ; Ding XQ
    Pancreatology; 2001; 1(4):336-42. PubMed ID: 12120212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor.
    Harikumar KG; Miller LJ
    J Biol Chem; 2005 May; 280(19):18631-5. PubMed ID: 15757907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of agonist binding to the type A cholecystokinin receptor.
    Miller LJ; Lybrand TP
    Pharmacol Toxicol; 2002 Dec; 91(6):282-5. PubMed ID: 12688369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely.
    Hadac EM; Ji Z; Pinon DI; Henne RM; Lybrand TP; Miller LJ
    J Med Chem; 1999 Jun; 42(12):2105-11. PubMed ID: 10377216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process.
    Escrieut C; Gigoux V; Archer E; Verrier S; Maigret B; Behrendt R; Moroder L; Bignon E; Silvente-Poirot S; Pradayrol L; Fourmy D
    J Biol Chem; 2002 Mar; 277(9):7546-55. PubMed ID: 11724786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin.
    Kennedy K; Gigoux V; Escrieut C; Maigret B; Martinez J; Moroder L; Fréhel D; Gully D; Vaysse N; Fourmy D
    J Biol Chem; 1997 Jan; 272(5):2920-6. PubMed ID: 9006937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the type A cholecystokinin receptor hormone-binding domain: use of contrasting and complementary methodologies.
    Ding XQ; Miller LJ
    Peptides; 2001 Aug; 22(8):1223-8. PubMed ID: 11457514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformationally readdressed CCK-B/delta-opioid peptide ligands.
    Nikiforovich GV; Kolodziej SA; Nock B; Bernad N; Martinez J; Marshall GR
    Biopolymers; 1995 Oct; 36(4):439-52. PubMed ID: 7578939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.
    Dong M; Miller LJ
    Peptides; 2013 Aug; 46():143-9. PubMed ID: 23770253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct identification of a second distinct site of contact between cholecystokinin and its receptor.
    Hadac EM; Pinon DI; Ji Z; Holicky EL; Henne RM; Lybrand TP; Miller LJ
    J Biol Chem; 1998 May; 273(21):12988-93. PubMed ID: 9582333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.